CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort StudiesFabienne Caby, Christoph Stephan, Marguerite Guiguet et al.|Clinical Infectious Diseases|2020Cited by 45
The EuroSIDA study: 25 years of scientific achievementsKamilla Grønborg Laut, Amanda Mocroft, Ole Kirk et al.|HIV Medicine|2019Cited by 34
Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency VirusFrédérique Chammartin, Amanda Mocroft, Alexander Egle et al.|Clinical Infectious Diseases|2023Cited by 27
Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort StudyHortensia Álvarez, Amanda Mocroft, Lene Ryom et al.|Clinical Infectious Diseases|2023Cited by 23
Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHEREAndrew Atkinson, Luis Prieto, Marcel Zwahlen et al.|Clinical Infectious Diseases|2020Cited by 21